Dermapharm stock sinks on mixed 1Q results
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Dermapharm Holding SE (DMPG)
Dermapharm Holding SE stock price live, this page displays ETR DMPG stock exchange data. View the DMPG premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Dermapharm Holding SE real time stock price chart below.
What Is the Dermapharm Holding SE Stock Price Today?
The Dermapharm Holding SE stock price today is 32.15.
What Is the Stock Symbol for Dermapharm Holding SE?
The stock symbol for Dermapharm Holding SE is ""DMPG.""
What Stock Exchange Does Dermapharm Holding SE Trade On?
Dermapharm Holding SE is listed and trades on the Xetra stock exchange.
Is Dermapharm Holding SE a Good Stock to Buy?
Determining whether Dermapharm Holding SE—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DMPG quote. (ISIN: DE000A2GS5D8)
What Is the Dermapharm Holding SE Stock Price Today?
The Dermapharm Holding SE stock price today is 32.15.
What Is the Stock Symbol for Dermapharm Holding SE?
The stock symbol for Dermapharm Holding SE is ""DMPG.""
What Stock Exchange Does Dermapharm Holding SE Trade On?
Dermapharm Holding SE is listed and trades on the Xetra stock exchange.
Is Dermapharm Holding SE a Good Stock to Buy?
Determining whether Dermapharm Holding SE—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DMPG quote. (ISIN: DE000A2GS5D8)
32.15
-1.20(-3.60%)
Closed·
Fair Value
An estimate of a Dermapharm's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.85
33.55
52 wk Range
30.15
42.50
DMPG Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
Unusual trading volume
1/2
Fair Value
An estimate of a Dermapharm's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.8533.55
52 wk Range
30.1542.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.80%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.80%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
DMPG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Dermapharm's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
49.50
Upside
+53.97%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- Dermapharm shares fall on flat growth outlook
- Investing.com
- Dermapharm stock sinks on mixed 1Q results
- Investing.com
- Dermapharm shares fall on flat growth outlook
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Dermapharm Holding SE Company Profile
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.
Compare DMPG to Peers and Sector
Metrics to compare | DMPG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDMPGPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.7x | 23.0x | −0.5x | |
PEG Ratio | 0.21 | 0.79 | 0.00 | |
Price/Book | 2.7x | 2.4x | 2.6x | |
Price / LTM Sales | 1.4x | 2.2x | 3.3x | |
Upside (Analyst Target) | 39.4% | 37.1% | 43.5% | |
Fair Value Upside | Unlock | 19.3% | 6.9% | Unlock |
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 49.50
(+53.97% Upside)
Earnings
Latest Release
May 15, 2025
EPS / Forecast
0.62 / --
Revenue / Forecast
302.40M / --
People Also Watch
FAQ
What Stock Exchange Does Dermapharm Trade On?
Dermapharm is listed and trades on the Frankfurt Stock Exchange stock exchange.
What Is the Stock Symbol for Dermapharm?
The stock symbol for Dermapharm is "DMPG."
What Is the Dermapharm Market Cap?
As of today, Dermapharm market cap is 1.73B.
What Is Dermapharm's Earnings Per Share (TTM)?
The Dermapharm EPS (TTM) is 1.92.
When Is the Next Dermapharm Earnings Date?
Dermapharm will release its next earnings report on 25 Aug 2025.
From a Technical Analysis Perspective, Is DMPG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Dermapharm Stock Split?
Dermapharm has split 0 times.
How Many Employees Does Dermapharm Have?
Dermapharm has 3610 employees.
What is the current trading status of Dermapharm (DMPG)?
As of 07 Aug 2025, Dermapharm (DMPG) is trading at a price of 32.15, with a previous close of 33.35. The stock has fluctuated within a day range of 31.85 to 33.55, while its 52-week range spans from 30.15 to 42.50.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.